Bismuth subsalicylate as potential treatment for Covid-19 pneumonia: A case series report

Abstract

Various literature cited suggests that bismuth may have usefulness against Covid-19 both in vitro and in vivo. During the course of caring for Covid-19 patients we administered bismuth subsalicylate to those who displayed diarrhea and/or gastric complaints. Using relatively conservative criteria, upon retrospective review, we noted marked improvement in oxygen requirements in most of the cases. This improvement was observed even when prior therapy with standard anti-Covid drugs had failed. Our overall impression is that these positive results support a detailed evaluation of bismuth as an adjunct treatment for the treatment of Covid-19.